Pharma Aims Torpedo At FCA After Bombshell 9th Circ. Ruling

A burgeoning campaign against the False Claims Act’s whistleblower mechanism is suddenly center stage at the Ninth Circuit, where pharmaceutical companies say a momentous new ruling “illustrates perfectly” the constitutional concerns of U.S. Supreme Court justices regarding FCA enforcement.

Continue reading →